IDEXX Laboratories (WKN: 888210) IDXX

Seite 1 von 1
neuester Beitrag:  04.05.22 18:41
eröffnet am: 08.02.18 15:51 von: Tamakoschy Anzahl Beiträge: 16
neuester Beitrag: 04.05.22 18:41 von: Tamakoschy Leser gesamt: 7700
davon Heute: 2
bewertet mit 0 Sternen

08.02.18 15:51 #1 IDEXX Laboratories (WKN: 888210) IDXX
http://www.idexx.de/corporate/home.html

https://www.idexx.com/en/about-idexx/investors/


Kurzporträt

Manufactures animal health products

IDEXX Laboratories, Inc. engages in the development, manufacture, and distribution of products and services for the animal veterinary, livestock and poultry, dairy and water testing markets.

It operates through the following business segments: Companion Animal Group; Water; Livestock, Poultry, and Dairy; and Other.

The Companion Animal Group segment refers to diagnostic and information technology-based products and services for the veterinary market.

The Water segment includes water quality products for testing of certain microbiological water contaminants.

The Livestock, Poultry, and Dairy segment involves diagnostic, health-monitoring, and food safety testing products for livestock and poultry health, and dairy products.

The Other segment comprises products for the human point-of-care medical diagnostics market with the company's pharmaceutical product line and out-licensing arrangements.

IDEXX Laboratories was founded by David Evans Shaw on December 19, 1983 and is headquartered in Westbrook, ME.

http://de.4-traders.com/IDEXX-LABORATORIES-9641/...pide&mots=idxx  
11.11.18 20:03 #2 Etwas günstiger
01.02.19 14:41 #3 Q4 Zahlen schlage Erwartungen
https://www.marketscreener.com/...dexx-4Q-Earnings-Snapshot-27948600/

https://www.marketscreener.com/...nd-Full-Year-2018-Results-27948509/

02/01/2019 | 06:53am EST
WESTBROOK, Maine (AP) _ Idexx Laboratories Inc. (IDXX) on Friday reported fourth-quarter earnings of $85.6 million.
The Westbrook, Maine-based company said it had net income of 98 cents per share.

The results topped Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for earnings of 90 cents per share.
The Animal diagnostic and health care company posted revenue of $549.4 million in the period, also exceeding Street forecasts. Three analysts surveyed by Zacks expected $545.6 million.
For the year, the company reported profit of $377 million, or $4.26 per share. Revenue was reported as $2.21 billion.
Idexx expects full-year earnings to be $4.66 to $4.78 per share, with revenue in the range of $2.38 billion to $2.42 billion.

 
01.05.19 16:40 #4 q1 wieder über Erwartungen
https://www.marketscreener.com/...dexx-1Q-Earnings-Snapshot-28514373/

05/01/2019 | 06:45am EDT
WESTBROOK, Maine (AP) _ Idexx Laboratories Inc. (IDXX) on Wednesday reported first-quarter earnings of $102.7 million.
On a per-share basis, the Westbrook, Maine-based company said it had net income of $1.17.
The results topped Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for earnings of $1.04 per share.
The Animal diagnostic and health care company posted revenue of $576.1 million in the period.
Idexx expects full-year earnings to be $4.76 to $4.88 per share, with revenue in the range of $2.38 billion to $2.42 billion.
Idexx shares have increased 25% since the beginning of the year. The stock has risen 19% in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on IDXX at https://www.zacks.com/ap/IDXX
Automated Insights, source Associated Press News  
31.10.19 18:07 #5 Q3 Über Erwartungen
https://www.marketscreener.com/...ondition-and-Results-of-O-29492368/

https://www.marketscreener.com/...dexx-3Q-Earnings-Snapshot-29489583/

Idexx: 3Q Earnings Snapshot

10/31/2019 | 06:46am EDT
WESTBROOK, Maine (AP) _ Idexx Laboratories Inc. (IDXX) on Thursday reported third-quarter net income of $108.8 million.
The Westbrook, Maine-based company said it had net income of $1.24 per share.
The results surpassed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for earnings of $1.13 per share.
The Animal diagnostic and health care company posted revenue of $605.3 million in the period, also exceeding Street forecasts. Three analysts surveyed by Zacks expected $597.4 million.
Idexx expects full-year earnings to be $4.72 to $4.78 per share, with revenue expected to be $2.4 billion.
Idexx shares have risen 47% since the beginning of the year. The stock has climbed 30% in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on IDXX at https://www.zacks.com/ap/IDXX
Automated Insights, source Associated Press News

 
02.02.20 16:01 #6 Q4 über Erwartungen - Kurs hat trotzdem Schnu.
https://www.marketscreener.com/...dexx-4Q-Earnings-Snapshot-29920185/

Idexx: 4Q Earnings Snapshot

01/31/2020 | 06:59am EST
WESTBROOK, Maine (AP) _ Idexx Laboratories Inc. (IDXX) on Friday reported fourth-quarter earnings of $90.5 million.
On a per-share basis, the Westbrook, Maine-based company said it had profit of $1.04.
The results beat Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for earnings of 91 cents per share.
The Animal diagnostic and health care company posted revenue of $605.4 million in the period, which also beat Street forecasts. Three analysts surveyed by Zacks expected $599.9 million.
For the year, the company reported profit of $427.7 million, or $4.89 per share. Revenue was reported as $2.41 billion.
Idexx expects full-year earnings to be $5.42 to $5.58 per share, with revenue in the range of $2.62 billion to $2.66 billion.
Idexx shares have risen roughly 9% since the beginning of the year. The stock has increased 37% in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on IDXX at https://www.zacks.com/ap/IDXX
Automated Insights, source Associated Press News

https://www.marketscreener.com/...nd-Full-Year-2019-Results-29920019/

Achieves revenue growth in Q4 of 10% on a reported and organic basis, driven by CAG Diagnostics recurring revenue reported and organic growth of 11%
Reports 19% year-over-year increase in Catalyst placements at new and competitive accounts in Q4, supporting full year growth of 16% in IDEXX's premium instrument installed base
Delivers full year EPS of $4.89, representing 15% growth on a reported basis and 21% on a comparable constant currency basis
Increases 2020 revenue guidance to $2,620 million - $2,655 million, reflecting consistent expectations for reported and organic revenue growth of 9% - 10.5%
Raises 2020 EPS outlook range by $0.12 to $5.42 - $5.58, reflecting expectations for continued strong operating trends, higher estimates for share-based compensation tax benefits and favorable adjustments to projected foreign exchange rates impacts
 
06.05.20 21:17 #7 Q1 2020
https://www.marketscreener.com/...dexx-1Q-Earnings-Snapshot-30502962/

Idexx: 1Q Earnings Snapshot
share with twitter share with LinkedIn share with facebook share via e-mail
0
04/30/2020 | 11:45am BST
WESTBROOK, Maine (AP) _ Idexx Laboratories Inc. (IDXX) on Thursday reported first-quarter profit of $111.8 million.

On a per-share basis, the Westbrook, Maine-based company said it had profit of $1.29.

The results beat Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for earnings of $1.23 per share.

The Animal diagnostic and health care company posted revenue of $626.3 million in the period, missing Street forecasts. Three analysts surveyed by Zacks expected $631.8 million.

Idexx shares have risen slightly more than 4% since the beginning of the year. The stock has climbed 18% in the last 12 months.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on IDXX at https://www.zacks.com/ap/IDXX

Automated Insights, source Associated Press News  
01.08.20 17:40 #8 Q2 Gute Zahlen
https://www.marketscreener.com/...dexx-2Q-Earnings-Snapshot-31029808/

dexx: 2Q Earnings Snapshot

07/31/2020 | 11:42am BST
WESTBROOK, Maine (AP) _ Idexx Laboratories Inc. (IDXX) on Friday reported second-quarter profit of $148.9 million.

On a per-share basis, the Westbrook, Maine-based company said it had profit of $1.72.

The results surpassed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for earnings of $1.20 per share.

The Animal diagnostic and health care company posted revenue of $637.6 million in the period, also exceeding Street forecasts. Three analysts surveyed by Zacks expected $580 million.

Idexx shares have risen 43% since the beginning of the year. The stock has risen 31% in the last 12 months.

 
29.10.20 14:33 #9 Q3 Erwartungen übertroffen
https://www.marketscreener.com/quote/stock/...ings-Snapshot-31639779/

Idexx: 3Q Earnings Snapshot

10/29/2020 | 10:51am GMT

WESTBROOK, Maine (AP) _ Idexx Laboratories Inc. (IDXX) on Thursday reported third-quarter profit of $146.2 million.

On a per-share basis, the Westbrook, Maine-based company said it had profit of $1.69.

The results topped Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for earnings of $1.42 per share.

The Animal diagnostic and health care company posted revenue of $721.8 million in the period, which also beat Street forecasts. Three analysts surveyed by Zacks expected $670.7 million.

Idexx shares have risen 62% since the beginning of the year. The stock has increased 59% in the last 12 months.  
29.10.20 14:45 #10 Q 3 Nachtrag
https://www.marketscreener.com/quote/stock/...arter-Results-31639565/

Achieves revenue growth of 19% on a reported basis and 18% on an organic basis driven by Companion Animal Group Diagnostics recurring revenue growth of 23% reported and 21% organic
High revenue growth supported by sustained strong global recovery in the pet healthcare market
Delivers EPS of $1.69, representing 36% growth on a reported basis and 47% on a comparable constant currency basis, reflecting benefits from high CAG Diagnostics recurring revenue gains and proactive cost controls  
02.02.21 16:49 #11 Q4 Top Zahlen - neues ATH
https://www.marketscreener.com/quote/stock/...ings-Snapshot-32334711/

4Q Earnings Snapshot
02/02/2021 | 11:49am GMT

WESTBROOK, Maine (AP) _ Idexx Laboratories Inc. (IDXX) on Tuesday reported fourth-quarter earnings of $174.8 million.

The Westbrook, Maine-based company said it had net income of $2.01 per share.

The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for earnings of $1.43 per share.

The Animal diagnostic and health care company posted revenue of $720.9 million in the period, which also topped Street forecasts. Four analysts surveyed by Zacks expected $681.5 million.

For the year, the company reported profit of $581.8 million, or $6.71 per share. Revenue was reported as $2.71 billion.

Idexx expects full-year earnings to be $7.39 to $7.71 per share, with revenue in the range of $3.07 billion to $3.12 billion.

Idexx shares have decreased 1.5% since the beginning of the year. The stock has risen 74% in the last 12 months.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on IDXX at https://www.zacks.com/ap/IDXX

Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News

https://www.marketscreener.com/quote/stock/...-2021-Outlook-32335507/


 
26.02.21 21:25 #12 IDEXX
Bin jetzt auch dabei. Die Growth Story stimmt und mich hat der hohe Anteil an wiederkehrenden Umsätzen überzeugt. Da ich 3-5 Jahre Zeit mitbringe, ist das Investment ein No-Brainer  
01.08.21 11:02 #13 Q2 Zahlen über Erwartungen
https://www.marketscreener.com/quote/stock/...ings-Snapshot-36016661/

Idexx: Q2 Earnings Snapshot
07/30/2021 | 11:41am BST

WESTBROOK, Maine (AP) _ Idexx Laboratories Inc. (IDXX) on Friday reported second-quarter profit of $202.6 million.

On a per-share basis, the Westbrook, Maine-based company said it had profit of $2.34.

The results exceeded Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for earnings of $2.01 per share.

The Animal diagnostic and health care company posted revenue of $826.1 million in the period, also exceeding Street forecasts. Four analysts surveyed by Zacks expected $781.5 million.

Idexx expects full-year earnings to be $8.20 to $8.36 per share, with revenue in the range of $3.17 billion to $3.21 billion.

Idexx shares have climbed 41% since the beginning of the year. The stock has increased 92% in the last 12 months.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on IDXX at https://www.zacks.com/ap/IDXX

Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News

https://www.marketscreener.com/quote/stock/...-Results-of-O-36023448/  
02.02.22 18:56 #14 IDEXX
02.02.22 18:58 #15 Q4 über Erwartungen

IDEXX Laboratories steigert Gewinn und Umsatz im 4. Quartal und gibt Prognose für 2022 ab
02.02.2022 | 13:12

(MT Newswires) -- IDEXX Laboratories (IDXX) meldete am Mittwoch für das vierte Quartal einen Gewinn pro Aktie von $1,83, verglichen mit $1,63 im Vorjahr.

Die von Capital IQ befragten Analysten erwarteten $1,72.

Der Umsatz von $801,1 Millionen lag über dem Vorjahreswert von $720,9 Millionen. Die von Capital IQ befragten Analysten hatten mit 781,8 Mio. $ gerechnet.

Für das Jahr 2022 erwartet das Unternehmen einen Gewinn je Aktie zwischen 9,27 und 9,59 Dollar bei einem Umsatz von 3,5 bis 3,6 Milliarden Dollar.

https://de.marketscreener.com/kurs/aktie/...ose-fur-2022-ab-37720598/

 
04.05.22 18:41 #16 Q1 und Ausblick schwach
IDEXX Laboratories Q1 Gewinnrückgang, Umsatzanstieg; Unternehmen senkt Ausblick für 2022
04.05.2022 | 13:20

(MT Newswires) -- IDEXX Laboratories (IDXX) meldete am Mittwoch für das erste Quartal einen Gewinn von $2,27 pro verwässerter Aktie, gegenüber $2,35 im Vorjahr.

Die von Capital IQ befragten Analysten hatten mit $2,24 gerechnet.

Der Umsatz für das Quartal, das am 31. März endete, lag bei 836,5 Mio. $, gegenüber 777,7 Mio. $ im Vorjahresquartal.

Die von Capital IQ befragten Analysten hatten $836,5 Millionen prognostiziert.

Für das Gesamtjahr 2022 rechnet das Tiergesundheitsunternehmen nun mit einem Gewinn je Aktie von 8,11 bis 8,35 Dollar, nachdem zuvor 9,27 bis 9,59 Dollar erwartet worden waren.

IDEXX rechnet für das Jahr 2022 mit einem Umsatz von 3,39 bis 3,47 Mrd. Dollar, nachdem zuvor 3,5 bis 3,57 Mrd. Dollar erwartet wurden.

Die Aktien des Unternehmens gaben im vorbörslichen Handel um 9% nach.

Kurs: 396.75, Veränderung: -39.21, Prozentuale Veränderung: -8.99

 
Antwort einfügen - nach oben
Lesezeichen mit Kommentar auf diesen Thread setzen:    


Bitte warten...